secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001654954-23-006222
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech Q2 net loss narrows to $2.33M; FDA agrees on Phase 3 endpoint for ARDS drug
--------------------------------------------------------------------------------

- Net loss of $2.33M ($0.12/share) vs $4.57M ($0.33/share) in Q2 2022; operating expenses down 47%.
- Cash and equivalents $7.47M; working capital $6.56M; raised $0.60M via ATM after quarter end.
- FDA agreed on primary endpoint for pivotal Phase 3 study of EB05 (paridiprubart) in ARDS patients.
- Canadian regulators authorized Phase 2 study of EB06 for vitiligo; Phase 2b topline results for EB01 in ACD reported.
- Plans to file IND for Phase 2 study of EB07 in systemic sclerosis (scleroderma).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495423006222/0001654954-23-006222-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495423006222/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-006222

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer